Log In
BCIQ
Print this Print this
 

milciclib maleate (PHA-848125)

  Manage Alerts
Collapse Summary General Information
Company Nerviano Medical Sciences s.r.l.
DescriptionOral inhibitor of cyclin-dependent kinases (CDKs) and neurotrophic tyrosine kinase receptor 1 (TrkA; NTRK1)
Molecular Target Cyclin dependent kinase (CDK) ; Neurotrophic tyrosine kinase receptor 1 (TrkA) (NTRK1)
Mechanism of ActionCyclin dependent kinase (CDK) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard Indication Cancer (unspecified)
Indication DetailsTreat thymic carcinoma
Regulatory Designation
PartnerTiziana Life Sciences plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$41.7M

$3.5M

$38.2M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/20/2015

$41.7M

$3.5M

$38.2M

Get a free BioCentury trial today